LMR Partners’s Teva Pharmaceuticals TEVA Stock Holding History

LMR Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.7M	Buy	+582,275	New	+$19.4M	0.07%	242
2025 Q2	–	Sell	-63,834	Closed	-$1.03M	–	1637
2025 Q1	$981K	Sell	63,834 -983	-2%	-$17.6K	0.01%	794
2024 Q4	$1.43M	Buy	+64,817	New	+$1.18M	0.01%	677
2019 Q4	–	Sell	-150,000	Closed	-$1.03M	–	545
2019 Q3	$1.03M	Buy	+150,000	New	+$1.15M	0.05%	166
2018 Q2	–	Sell	-62,500	Closed	-$1.18M	–	575
2018 Q1	$1.18M	Hold	62,500	–	–	0.12%	161
2017 Q4	$1.18M	Buy	+62,500	New	+$940K	0.12%	161

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

LMR Partners's TEVA Position: Q2 2026 in Review

LMR Partners opened a new position in Teva Pharmaceuticals (TEVA) in Q2 2026: 582,275 shares worth $19.7M. The stake represents 0.07% of the portfolio and ranks #242 among its holdings. This is a return to the name: LMR Partners previously reported a position in TEVA as recently as Q1 2025.

LMR Partners first reported a position in TEVA in Q4 2017 and has held it in 6 quarters since. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

LMR Partners held 582,275 shares of Teva Pharmaceuticals worth $19.7M as of Q2 2026.
Teva Pharmaceuticals was a new LMR Partners position in Q2 2026.
Teva Pharmaceuticals made up 0.07% of LMR Partners's portfolio in Q2 2026, its #242 holding.
LMR Partners first reported a position in Teva Pharmaceuticals in Q4 2017 and has held it in 6 quarters since.
675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.